Introduction
The incidence of nosocomial colonisation and infections due to Enterococcus spp., with those due to Enterococcus faecium the most prevalent, has risen steadily during the 1980s. At the same time, these bacteria have acquired resistance to aminoglycosides, 3-lactams and glycopeptides." Enterococci are opportunist pathogens and medical advances ensure an increasing population of patients vulnerable to nosocomial endogenous and exogenous infection' with enterococcal bacteraemia, particularly caused by E faecium, a marker for serious underlying disease. 4 5 Clusters of colonisation and infections due to enterococci have occurred among patient subsets susceptible as a result of immunosuppressive disease or treatment and epidemiological studies combined with molecular typing have correlated patient colonisation with dissemination of susceptible and resistant strains. 2 The success of enterococci as nosocomial pathogens is ensured by their habitat and resistance to desiccation, heat, some disinfectants, and most antimicrobial agents.2 Their normal habitat is the large intestine where they may encounter antimicrobial agents excreted by this route, exchange genetic material with other bacterial genera and whence they contaminate the environment. Intrinsic Aminoglycoside modifying enzymes (AMEs) are the most important mechanisms mediating high level resistance (HLR). Each AME may confer HLR to more than one aminoglycoside and a single enterococcal strain may acquire several AMEs.8 Although most AMEs are plasmid mediated and transferable, E faecium differs from other enterococci in its production of a chromosomally mediated AME. This species specific enzyme, although not conferring HLR, abolishes synergy between cell wall active agents and all aminoglycosides except streptomycin, amikacin and gentamicin.'°" Enterococci may acquire a plasmid or transposon mediated AME exhibiting both 2"-phosphotransferase and 6'-acetyltransferase activities, which confers HLR to gentamicin and all other commercially available aminoglycosides except streptomycin.'2 '3 Against strains of Efaecium which acquire this enzyme, because of its chromosomal AME (vide supra), only streptomycin achieves synergy. However, both Enterococcus faecalis and E faecium may acquire another AME, a 6'-adenyltransferase, which confers HLR to streptomycin. This enzyme is usually co-transferred with a 3'-phosphotransferase which confers HLR to kanamycin; this enzyme also abolishes synergy with amikacin without conferring HLR. 8 Following its introduction in the 1 950s, vancomycin was used sparingly due to impurity of early preparations and common side effects. The agent was usually reserved for patients allergic to ,-lactams. Since 1970, it has been prescribed extensively for S aureus infections in patients with end stage renal failure on haemodialysis. It is not removed during dialysis and can be conveniently administered weekly. Much of its increased consumption in the past decade is accounted for in the treatment of intravenous line infections due to S epidermidis.
Resistance to vancomycin remained insignificant clinically for almost 30 Recently, vancomycin dependent E faecalis and E faecium have been described. 26 27 The mechanism has not been elucidated.
Laboratory aspects Important differences exist among the species of enterococci with regard to penicillin, aminoglycoside and glycopeptide resistance patterns (vide supra). For this reason and for epidemiological information enterococci causing serious infections should be fully identified; a minimum requirement is differentiation of the species isolated most frequently from clinical material, Efaecalis and Efaecium. Commercially available kits are useful, supplemented by tests from other schemes,28 or the advice of a reference laboratory may be sought.
HIGH LEVEL AMINOGLYCOSIDE RESISTANCE
Enterococci implicated in serious infections must be screened for high level aminoglycoside resistance which predicts lack of synergy with cell wall active agents.9 " Only gentamicin and streptomycin need be tested routinely. Because the 3'-phosphotransferase AME abolishes synergy between amikacin and cell wall active agents without conferring HLR to that aminoglycoside, HLR to kanamycin must be sought if the intention is to use amikacin (vide supra).8 '4 Screening avoids MIC determinations, the inclusion of aminoglycosides in in vitro synergy tests and unnecessary administration of aminoglycosides. Simple and reliable methods are available for screening.29 Disc diffusion testing with 120 gg gentamicin and kanamycin discs and 300 jg streptomycin discs is cheap and reliable. Provided the standard procedure is followed, a zone diameter of 6 mm indicates HLR and most other strains have zones of > 10 mm; isolates giving zones of 7-9 mm should be checked by a different method. Agar dilution using brain heart infusion broth containing 500 gg/ml gentamicin or 2000 jg/ml streptomycin is an alternative. For multipoint testing an inoculum of 106 colony forming units (cfu) per spot is optimal. Broth microdilution using gentamicin at 500 ,ug/ml or streptomycin at 1000 gg/ml and an inoculum of 10' cfu/ml is sensitive for detecting HLR to these agents. Although the E test (AB Biodisk, Solina, Sweden) detects HLR to gentamicin, detection of HLR to streptomycin is more problematic unless a low range strip (1024 jg) is used or incubation is prolonged to 48 hours.30 31 Wade, Uttley GLYCOPEPTIDE RESISTANCE High level glycopeptide resistance is readily detected using 30 ig discs. In contrast, low level vancomycin resistance is easily missed by laboratories using disc diffusion susceptibility testing unless the disc contains 5 ,ug vancomycin, ideally with E faecalis ATCC 51299 (a VanB strain), as control.32 Screening for resistance with brain heart infusion agar containing 6 gig/ml vancomycin is sensitive. Multipoint inoculation with 105 to 106 cfu per spot is recommended. 29 Inoculation with a swab, however, has little effect on the results. The E test identifies vancomycin resistance in enterococci.3'" For enterococci causing serious infections, the MICs of vancomycin and teicoplanin must be determined.
HIGH LEVEL PENICILLIN RESISTANCE
Disc diffusion using a 10 jg disc identifies ampicillin resistance whether using the Kirby Bauer method or disc diffusion with E faecalis ATCC 29212 as control.32 However, these methods do not differentiate enterococci with high level penicillin resistance (MICs > 128 ,ug/ml) from those with lower level resistance (MICs 16-32 ,ug/ml). As the latter may be killed by a combination of penicillin and aminoglycoside, the MICs of penicillin or ampicillin should be determined for enterococci causing endocarditis or other serious infections. The E test is a reliable method for measuring MICs.
DETECTION OF P-LACTAMASE
,-lactamase producing enterococci exhibit a notable inoculum effect: penicillin resistance may not be demonstrated unless a high inoculum-for example, 10' cfu/ml, is used. Commercial tests for 3-lactamase detection are recommended; however, a strain of 3-lactamase producing E faecalis that does not hydrolyse nitrocefin has been reported. 34 Control of resistant enterococci in hospitals Outbreaks of colonisation/infection by enterococci with up to 53% of infections typically occurring on high dependency units, such as intensive care and oncology wards, although general wards may also be involved. Some studies designed to identify risk factors for acquisition of a resistance trait have selected as controls patients acquiring enterococci lacking that trait. The conclusions are that broad spectrum cephalosporins and aminoglycosides seem to be risk factors for acquisition of gentamicin resistant rather than other E faecalis strains. Similarly, penicillin, ampicillin, co-trimoxazole, third generation cephalosporins, clindamycin, and imipenem may select for ampicillin resistant rather than ampicillin susceptible enterococci. On the basis of these and other studies, adjusting antimicrobial policy will probably play an important role in control of spread of resistant enterococci. For example, inappropriate use of vancomycin has been addressed by the US Department of Health which has recently published guidelines in an attempt to reduce selective pressure on vancomycin resistant enterococci. 35 However, it is difficult to envisage which antimicrobials will not select for enterococci, especially E faecium. Efforts must focus on curtailing antimicrobial consumption generally as well as policing the classes of antimicrobials used.
